Rocket Pharmaceuticals (RCKT) – Investment Analysts’ Recent Ratings Updates

Rocket Pharmaceuticals (NASDAQ: RCKT) has recently received a number of price target changes and ratings updates:

• 3/12/2025 – Rocket Pharmaceuticals is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $50.00 price target on the stock.
• 3/3/2025 – Rocket Pharmaceuticals had its price target raised by analysts at Scotiabank from $51.00 to $52.00. They now have a “sector outperform” rating on the stock.
• 3/3/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $15.00. They now have a “neutral” rating on the stock.
• 3/3/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Canaccord Genuity Group Inc. from $39.00 to $36.00. They now have a “buy” rating on the stock.
• 2/28/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Chardan Capital from $62.00 to $54.00. They now have a “buy” rating on the stock.
• 2/28/2025 – Rocket Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $52.00 to $42.00. They now have a “buy” rating on the stock.

Rocket Pharmaceuticals Price Performance

Shares of RCKT traded up $0.07 during mid-day trading on Wednesday, reaching $8.42. 616,031 shares of the stock traded hands, compared to its average volume of 986,684. The company has a market cap of $897.29 million, a price-to-earnings ratio of -3.06 and a beta of 1.03. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $10.06 and a 200 day moving average price of $13.79. Rocket Pharmaceuticals, Inc. has a 1 year low of $8.06 and a 1 year high of $28.67.

Rocket Pharmaceuticals (NASDAQ:RCKT) last issued its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. As a group, equities research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently modified their holdings of RCKT. Wellington Management Group LLP lifted its stake in Rocket Pharmaceuticals by 24.5% in the fourth quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company’s stock worth $175,919,000 after acquiring an additional 2,753,033 shares during the period. Vanguard Group Inc. lifted its position in shares of Rocket Pharmaceuticals by 18.8% in the 4th quarter. Vanguard Group Inc. now owns 6,577,595 shares of the biotechnology company’s stock worth $82,680,000 after purchasing an additional 1,040,655 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of Rocket Pharmaceuticals by 3.8% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock valued at $83,001,000 after purchasing an additional 165,911 shares in the last quarter. Maverick Capital Ltd. increased its position in shares of Rocket Pharmaceuticals by 4.8% during the third quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company’s stock valued at $76,072,000 after buying an additional 190,360 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Rocket Pharmaceuticals by 111.0% in the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company’s stock worth $50,343,000 after buying an additional 2,106,699 shares in the last quarter. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.